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 Inflammation can be up-regulated by microglia and macrophages through the 
release of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α). 
Excess production of TNF-α can lead to a variety of diseases and even tissue necrosis.  
Recently, the expression of alpha seven acetylcholine receptors (α7AChR) by microglia 
have been shown to decrease the amount of TNF-α released. This anti-inflammatory 
pathway has been studied extensively where researchers are able to reduce TNF-α 
concentration through α7AChR expression and increases in the concentration of its 
ligand. I have shown that Neuregulin is able to increase the expression of α7AChR in 
microglia and macrophages.  
Using three immortalized cell lines, BV-2, EOC-20 and RAW 264.7, and primary 
microglial cells harvest from mice I investigated the role that neuregulin plays in the anti-
inflammatory process. Neuregulin signals through the ErbB receptors, a family of 
tyrosine kinase receptors, to facilitate the effects on ACh expression. My results show 
that ErbB4 is expressed in BV-2, EOC-20 and RAW 264.7 cell lines while ErbB2-4 
receptors are expressed in primary microglia. As well, I was able to show that ErbB4 
became phosphorylated upon binding to NRG in immortalized cell lines.   
Using an Enzyme Linked Immunsorbent Assay to analyze TNF- α concentration 
in microglia and macrophages, I was able to demonstrate that increased levels of 
α7AChRs did not result in a reduction in TNF-α concentration. These results showed that 
NRG is able to increase α7AChRs in microglia and macrophages after the 
phosphorylation of the ErbB4 receptors. As well, this increase in α7AChR does not relate 
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to a reduction in TNF-α, thus under these experimental conditions does not have an effect 
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Chapter 1 Introduction 
 
1.1 The central nervous system and inflammation 
 
 The central nervous system (CNS) is an immune-privileged site that is inaccessible 
to cells of the systemic immune system due to the blood brain barrier. The blood brain 
barrier is composed of endothelial cells linked together by tight junctions and exclude cells 
from circulating blood.  As a result of this physical separation, the CNS has its own 
immune system composed of microglial cells. These resident immune cells have the 
capability to degrade foreign invaders and recruit others for help, principally by increasing 
the permeability of the blood brain barrier and allowing for cells of the systemic immune 
system to enter into the CNS. 
The immune response normally progresses from an innate to an adaptive response. 
In the initial steps of an innate response inflammation is a normal physiological process that 
occurs throughout the body where cells of the immune system are recruited to areas of 
infection, injury and trauma (Pavlov et al., 2003). While this is normally a beneficial 
process where the cells of the immune system aid in the clearing of damaged tissue, debris 
and pathogens, it can be detrimental especially when this type of response occurs in the 
central nervous system (Pavlov et al., 2003). When a local inflammatory response is 
uncontrolled, systematic inflammation may ensue resulting in shock, possible organ failure, 
swelling in the brain and spinal cord and even death (Pavlov et al., 2003). Innate 
deregulation can also lead to a variety of auto-inflammatory diseases including arthritis, 
asthma, Graves disease and Crones disease (Targan et al., 1997; Salvi et al., 2000).  In 
1 
 
many of these diseases there is an over expression of Tumour Necrosis Factor alpha (TNF-
), a pro-inflammatory cytokine (Targan et al., 1997; Salvi et al., 2000; Chabot et al., 
1997). 
 
1.2 The innate immune response  
 
 The innate response is the initial response to a foreign invader or injury. It is often 
initiated by the presence of pathogen-associated molecules (PAMPs), molecules broadly 
shared by pathogens but distinguishable from host molecule. PAMPs are recognized by 
cells of the immune system, in particular antigen presenting cells (APC).  APC are a group 
of cells that are capable of internalizing an antigen, degrading it and presenting it on their 
major histocompatibility complex (MHC) class two receptors to T lymphocytes (Nguyen et 
al., 2002). In the CNS, microglia are able to perform as APCs upon encountering a 
pathogen. Upon invasion of the foreign invader into the CNS, the PAMPs on the intruder 
are recognized by Toll-Like Receptors (TLR). Depending on the type of PAMP present, a 
different TLR will be activated  for instance, TLR-4 is activated in response to 
Lipopolysaccharide (LPS) found on gram-negative bacteria (Olson and Miller, 2004; 
Nguyen et al., 2002). PAMPs binding to TLRs induce APC activation, which leads to 
secretion of a variety of chemokines and cytokines responsible for recruiting peripheral 
macrophages and T cells. The activation of microglial cells leads to the induction of the 
nuclear factor kappa-beta (NF-) pathway where it’s activation leads to a transcription of 
a variety of pro-inflammatory cytokines including TNF- (Olson and Miller, 2004; Wang 










Figure 1.1: Microglial activation and release of TNF-. Microglia reside in a resting 
state (left) until they encounter a foreign invader or are activated by cytokines (right). LPS 
on gram-negative bacteria (or other PAMPs) stimulate Toll-like receptors (TLRs) on the 
surface of microglia activating the cell (1).  TLR-4 in association with CD14 recognizes 
LPS and through their interaction with the adaptor protein MyD88 (2) they stimulate the 
NFB signaling pathway and trigger TNF- transcription (3).  TNF- induces neutrophil 
proliferation, activates more microglia and provides a positive feedback loop to increase 





Inflammation occurs in conjunction with the innate response and is initiated by 
similar mechanisms. Inflammation begins with contraction of smooth muscle around the 
large blood vessels to increase the flow of blood through capillaries at the site of infection. 
Next extravasation occurs, allowing the once tight junctions between endothelial cells of 
the blood brain barrier to become permeable to cells of the immune system (Figure 1.2) 
(Stamatovic et al., 2008). This process culminates with diapedesis where cytokines and 
complement molecules act as adhesion molecules allowing circulating leukocytes to attach 
to the surface of endothelial cells, flatten and squeeze through the intervening spaces (Sage 
and Carman, 2009).   
 
Inflammation is maintained through activated macrophages through the release of 
different inflammatory cytokines such as TNF- and IL-1 after their encounter with the 
foreign invader. TNF- and IL-1 bind to receptors on endothelial cells that are required for 





Figure 1.2: Inflammation. Inflammation begins with recognition of a foreign invader or 
damage (1). In the case of CNS, most foreign invaders are recognized by microglia. Upon 
interaction microglia become activated (2) and secrete TNF- to activate surrounding 
microglial cells (3) and to initiate vasodilation. The tight junctions of endothelial cells that 
create the blood brain barrier loosen as endothelial cells constrict in response to a foreign 
invader (4). This contraction allows for leukocytes of the systemic immune system to 
squeeze through the barrier and enter into the CNS (5). Cells of the systemic immune 







1.3 Microglia: The resident CNS immune cell 
 
 The main cellular mediators regulating inflammation in the brain are microglia. 
Derived from myeloid cells of the periphery, these resident immune cells comprise around 
12% of the total cell population in the brain (Block et al., 2007). Upon activation by foreign 
invaders, microglia change from a predominantly resting state that is characterized by an 
amoeboid morphology to an active state. This activation allows for better recognition of 
pathogens, signaling to other immune cells and induces the transcription of cytokines. 
Microglia are key mediators of innate immunity because they secrete a variety of cytokines, 
are active in the phagocytosis of debris and pathogens and are involved in the recruitment 
of other immune cells and activation of the adaptive immune response (Wang et al., 2003; 
Pavlov et al., 2003; Streit et al., 2004; Raivich and Banati, 2004; Matsunaga et al., 2001).  
 Microglia have the ability to be both beneficial and harmful to the CNS depending 
on the level of stimulation they receive and the cytokines subsequently released. Microglia 
can be quite destructive to the CNS when there is an overproduction of superoxides, 
nitrogen oxide and TNF-; all molecules responsible for tissue damage and dysregulation 
of inflammation. Microgliosis, a state in which microglia become activated, can lead to 
these increases in inflammatory molecules and are  correlated to a variety of 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, HIV dementia, Multiple 
Sclerosis and Huntington’s disease (Streit et al., 2004; Block et al., 2007; Nguyen et al., 






1.4 Microglia and the anti-inflammatory pathway 
 
 Research has shown that in the PNS, macrophages can regulate the systemic 
inflammatory response via 7AChRs (Wang et al., 2003; Jonge and Ulloa, 2007).  
7AChR expression on macrophages has been shown to decrease the amount of TNF-α 
released in response to an assault in the PNS (Wang et al., 2003) (Figure 1.3). The 
reduction in TNF-α expression results in a decrease in the inflammatory response. Being 
able to mediate the inflammatory response could result in potential therapies for diseases 
where inflammation is responsible for the majority of damage.  
 
 Microglia have also been shown to be able to participate in this anti-inflammatory 
control through the expression of 7AChR (Shytle et al., 2004). It is not surprising that 
7AChRs are present in both microglia and macrophages since they are derived from the 
same progenitor cell.  Finding the pathway responsible for regulating the transcription of 







Figure 1.3: Microglia and the anti-inflammatory pathway.  Acetylcholine is an 
important neurotransmitter in the brain that signals through nicotinic (ligand-gated ion 
channels) or muscarinic (G-protein coupled receptors). The binding of a specific subset of 
nicotinic acetylcholine receptors, 7AChR, are able to regulate inflammation through a 
mechanism called “nicotinic anti-inflammatory pathway.” In this pathway, inflammation is 
regulated through the binding of nicotine or acetylcholine to 7AChR, which inhibits the 





1.5 Neuregulin and the ErbBs 
 
Neuregulins are a family of glycoproteins that have diverse roles in both CNS and 
PNS (Falls, 2003; Dimayuga et al., 2002; Zhenfeng et al., 2004).  Historically, the NRG 
family has included names such as: acetylcholine receptor-inducing activity (ARIA), neu 
differentiation factor (NDF), glial growth factor (GGF), heregulin (HRG) and 
sensorimotor-derived factor (SMDF). All of these names were originally derived from their 
described functions within the CNS and PNS but later were reconciled under the neuregulin 
nomenclature based on similarities in structure. NRG is now classified based on which of 
the four NRG genes it comes from, NRG1-4.  The functional differences of each NRG 
glycoprotein arise due to alternative splicing and differential promoter usage within the 
neuregulin gene but are still classified according to its origin (Dimayuga et al., 2003).  
NRG-1 and -2 share the highest sequence homology with each other, while NRG-3 
and 4 are distantly related to NRG-1 (Buananno and Fischbach, 2001; Falls 2003). NRG-1 
was the first gene to be cloned, is the most widely expressed and the most extensively 
researched.  NRG-1 is expressed in neurons, glial cells, heart, muscle, liver, stomach, lung, 
kidney, spleen and skin where it has been implicated in various biological processes at the 
neuromuscular junction, including organizing the postsynaptic membrane, the regulation of 
nicotinic acetylcholine receptor (AChR) transcription and the induction of muscle spindle 
formation (Buananno and Fischbach, 2001; Falls, 2003; Rimer, 2003; Jacobson et al., 
2004). NRG-1 is used in this thesis because of its ability to regulate AChR transcription in 
muscle cells. Of the remaining NRGs, NRG-2 is expressed in heart and CNS, NRG-3 is 
found only in CNS and NRG-4 is found within the PNS, pancreas and skeletal muscle 
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(Buonanno and Fischbach, 2001).  Ultimately the mechanism of NRG action depends on its 
binding to a heterogenous family of receptor tyrosine kinases related to the EGF receptor.  
NRG binds and signals through the ErbB receptors, a family of tyrosine kinase 
receptors consisting of four members, ErbB1-4 (Yarden and Sliwkowski, 2001). NRG can 
bind directly to two members of this family; ErbB3 and ErbB4.  Once bound, these 
receptors can form homodimers, in the case of ErbB4, or recruit ErbB1 or ErbB2 to form 
heterodimers (Buananno and Fischbach, 2001). Binding of NRG to the ErbBs is via an 
epidermal growth factor (EGF) domain common to all neuregulins (Buananno and 
Fischbach, 2001). Binding initiates phosphorylation leading to a variety of signaling 
cascades that can result in apoptosis, cell migration, growth, adhesion or differentiation 
depending on the  ErbB receptor dimer that NRG binds (Yarden and Sliwkowski, 2001) 








Figure 1.4: Neuregulins and the ErbB receptors.  There are a variety of ligands that can 
bind to the ErbB receptors (red), including the NRGs (blue). Depending on the ligand, 
along with different homodimer and heterodimer receptor combinations, will signal a 
variety of signaling ending with apoptosis, migration, growth, adhesion and differentiation 
of the cell. NRG1 can bind to ErbB3 and ErbB4 in any combination while NRG2-4 can 





ErbB2-4 are three ErbB receptors that are investigated in this thesis and are critical 
for NRG-1 signaling. Of these receptors, ErbB2 currently has no known ligand but is 
recruited to form heterodimers with the other ErbB receptors (Yarden and Sliwkowski, 
2001; Feroz et al., 2002). ErbB3 is found expressed in many different types of neural cells 
and epithelial cells. Devoid of intrinsic kinase activity it forms heterodimers with the other 
ErbB receptors to initiate signaling. The combination of ErbB2-ErbB3 results in a 
heterodimer that binds effectively to NRG-1 and is a potent stimulator of acetylcholine 
receptor transcription.  
In the CNS, ErbB3 is found expressed in oligodendrocytes, the glial cell responsible 
for myelinating axons of neurons (Feroz et al., 2002; Yarden and Slwkowski, 2001; 
Cannella et al., 1999). ErbB4 is also found in the central nervous system and is able to bind 
to all four neuregulin isoforms. ErbB4 expression is seen throughout the neural cell 
population and is upregulated in response to injury (Erlich et al., 2000). ErbB4 is unique in 
comparison to the other three receptors where it has four different isoforms generated 
through mRNA splicing (Carpenter, 2003). Two of the isoforms (JM-a and JM-b) are 
membranous while the other two are cytoplasmic (CYT-1 and CYT-2) (Carpenter, 2003; 
Sharif et al., 2009) but all four isoforms are expressed within the central nervous system 










1.6 Neuregulin and regulating expression of acetylcholine receptors 
  
Prior to implementing the presently used neuregulin nomenclature NRG-1, one 
isoform was known by the name ARIA for acetylcholine receptor-inducing activity 
(Fischbach and Rosen, 1997).  ARIA was discovered due to its ability to increase AChR 
gene expression at the neuromuscular junction (NMJ) (Fischbach and Rosen, 1997). ARIA 
now NRG-1,  is released from the developing motor neuron terminal, activating its receptor 
(ErbB2-ErbB3) on the post synapse thereby inducing AChR gene expression (Pun et al., 
1997).  
At the neuromuscular junction, neuregulin is involved with the induction of a signal 
transduction cascade ending with the activation of AChR subunit gene transcription (Falls, 
2003). The cascade starts with the binding of NRG-1 to the ErbB2-ErbB3 heterodimer 
complex. This binding induces the phosphorylation of the receptors and the subsequent 
activation of the Ras/Raf/ERK MAPK pathway. The end result of this signaling event is the 
transcription of AChR in muscle cells (Figure 1.5). If NRG is able to regulate AChR in 
muscle cells, then it is possible that a similar regulation of AChR can occur in microglial 







Figure 1.5: Neuregulin induces acetylcholine receptor transcription at the NMJ. In 
muscle cells, activation of ErbB tyrosine phosphorylation by NRG-1 causes an association 
with the adaptor protein Shc. This complex stimulates the Ras/Raf/ERK mitogen-activated 
protein kinase (MAPK) pathway. Briefly, this signaling pathway ends with the 
transcriptional upregulation of AChR at the neuromuscular junction. Neuregulin is 







1.7 Experimental objectives of this study 
  
This study aims to investigate the possible effects NRG may have on microglia. In 
particular I am interested in the possible up-regulation of 7AChR expression and NRG’s 
potential to regulate inflammatory responses. I hypothesize that the addition of NRG may 
increase the expression of 7AChR.  
Without ErbB expression, NRG would be unable to bind microglia to effectively 
mediate changes in gene expression or ultimately inflammation. Due to inconsistencies in 
the literature (Erlich et al., 2000; Dimayuga et al., 2002; Gerecke et al., 2001; Cannella et 
al., 1999; Chaudhury et al., 2003) my initial experiments examined ErbB receptor 
expression in primary microglia and several microglial cells lines via immunoblot. 
Immunoblots of 7AChR expression were compared in untreated, NRG treated, NRG and 
LPS treated and LPS treated cells to determine these molecules effects on 7AChR 
expression.  
 Lastly, to observe NRG’s affect on the inflammatory response TNF- was 
quantified using an ELISA. Again, samples were treated with NRG, LPS and NRG and 
LPS alone. Since TNF- is a pro-inflammatory cytokine, an increase in expression 
typically results in a stronger immune response. ACh is also added because it is the ligand 
for 7AChR and has been shown to inhibit the expression of TNF- (Wang et al., 2003). 
Therefore it is hypothesized that NRG treatments in combination with ACh should lead to a 







Figure 1.6: Proposed mechanism of NRG action on AChR.  Neuregulin signals through 
the ErbB receptors (1) to increase the transcription of 7AChR (2). The presence of 
7AChR decreases the production of TNF- in response to a foreign invader by inhibiting 
the NF-B pathway (3).  When microglia become activated through the binding of LPS, 
present in gram-negative bacteria, to TLR-4 (4) and the subsequent activation of NF-B, 
TNF- that would normally be transcribed is inhibited (5). This elimination of TNF- 
affects the inflammatory pathway by hindering the ability of microglia to attract system 





Chapter 2 Materials and Methods 
 
2.1 Cell culture 
 
2.1.1 Cell lines 
 
 EOC-20 cells, a mouse microglial cell line  ( CRL-2469; ATCC), were cultured in 
Dulbecco’s modified Eagle’s medium (Wisent, St. Bruno, QC) with 4mM L-glutamine 
supplemented with 10% fetal bovine serum (Wisent), 20% LADMAC Conditioned media, 
100IU/mL penicillin and 100mg/mL streptomycin (Wisent). Cells were grown at 37C in a 
5% CO2 in air atmosphere with culture medium renewal every 2 to 3 days. All subsequent 
passages were performed at a split ratio of 1:3.   
 The LADMACs, mouse lymphoblast cell line (CRL-2420; ATCC) was cultured for 
the production of colony stimulating factor-1 (CSF-1).  LADMACs were grown in Eagle’s 
Minimum Essential medium (Wisent) supplemented with 10% fetal bovine serum, 
100IU/mL penicillin and 100mg/mL streptomycin. Cells were grown at 37C in a 5% CO2 
in air atmosphere with medium renewal every 2 to 3 days. All subsequent passages were 
performed at a split ratio of 1:3.  Once cells reached confluency, medium was replaced and 
then not renewed to allow for high concentrations of CSF-1 to build up. At 5 to 7 days, this 
CSF-1 enriched medium (also known as conditioned medium) was collected and 
centrifuged at 125 x g for 10 minutes at room temperature. Supernatant was then filter 




 BV-2 is a murine microglial cell line, obtained as a gift from Dr. Michael J. Strong 
(University of Western Ontario, London, ON). BV-2 cells were cultured in RPMI 1640 
(Wisent) supplemented with heat-inactivated fetal bovine serum to a final concentration of 
10%, 100IU/mL penicillin and 100mg/mL streptomycin (Wisent). Similar to our other cell 
lines, cells were grown at 37C in a 5% CO2 with medium renewal every 2 to 3 days. When 
cells were passaged they were split at a 1:5 ratio.  
The RAW 264.7 murine macrophage cell line (TIB-71, ATCC) was cultured in a 
manner similar to BV-2 cells. Passage of these cells was performed at a split ratio of 1:3 to 
1:6. 
C2C12, a mouse myoblast cell line (CRL-1772; ATCC) was cultured to provide 
ErbB2 and ErbB3 positive cell extracts (Rimer, 2003).  Cells were cultured in Dulbecco’s 
modified Eagle’s medium low glucose (Wisent) supplemented with fetal bovine serum to a 
final concentration of 10%, 100IU/mL penicillin and 100mg/mL streptomycin. Cells were 
grown at 37C in a 8% CO2 in air atmosphere with medium renewal every 2 to 3 days. All 
subsequent passages were performed at a split ratio of 1:10 when cells reached 80% 
confluency. Myotubes were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 2% Horse Serum (Wisent), 100IU/mL penicillin and 100mg/mL 
streptomycin.  
Similarly, HeLa S3 cells derived from a human cervical epithelium line (CCl-2.2, 
ATCC) were cultured to provide extract positive for ErbB4 expression (Sundvall et al., 
2008). Culture conditions for HeLa S3 were similar to BV-2 and RAW cells.  All 




2.1.2 Isolation of microglia from mice 
 
 Primary mixed glial cultures were prepared from the cerebral cortices of 1- to 2-
day-old C57BL/6 mice. Each culture was derived from a single brain.  After the removal of 
the meninges, the brain was washed in PBS treated with gentamicin, penicillin and 
streptomycin. The washed cortices were minced and pushed through a 70m Nylon mesh 
cell strainer (BD Falcon, Mississauga, ON) followed by filtering through a 40m Nylon 
mesh cell strainer (BD Falcon). Cell suspensions were digested in 30mL Hank’s balanced 
salt solution (HBSS) (Invitrogen, Carlsbad, CA) with the addition of  DNAse 1 (28U/mL) 
and collagenase type B (0.2mg/mL) for 1 hour at 37C at 160rpm. Isolates in HBSS were 
collected and centrifuged at 800 x g for 10 minutes. Dissociated cells were transferred to a 
35mm tissue culture dish (BD Falcon) and cultured in Dulbecco’s modified Eagle’s 
medium with 4mM L-glutamine supplemented with 10% fetal bovine serum, 20% 
LADMAC Conditioned media (CSF-1), 100IU/mL penicillin and 100mg/mL streptomycin. 
Cells were grown at 37C in a 5% CO2 in air atmosphere with medium renewal at 24 hours 
post-plating and every 2 to 3 days after.  
 
2.1.3 Microglia isolation from mixed glial culture 
 
 Two weeks after initiating the culture, supernatant were collected by shaking at 160 
rpm following treatment with 10% (v/v) trypsin/EDTA (1:1) (Wisent) for 1 hour at 37C. 
Isolates were centrifuged at 800xg for 10 minutes and the resulting cell pellets were 
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resuspended in growth media and plated on collagen coated plates [0.1% collagen from calf 
skin (Sigma) and 0.1N acetic acid]. After thirty minutes medium was aspirated to remove 
any unattached cells, which are mostly astrocytes, and the medium refreshed. Cells were 
then grown for 24 hours before harvesting.  
To assess the purity of primary cell cultures, the assumed pure plate of microglial 
cells was trypsinized and plated onto glass plates coated with collagen. After a 24 hour 
incubation period Acetylated Low Density Lipoprotein labeled with 1, 1’-dioctagecyl-
3,3,3’,3’-tetramethylindo-carbocyanine perchlorate (BT-902; Biomedical Technologies, 
Stoughton, MA) was added and incubated for four hours at 37ºC (Voyta et al., 1984; 
Giulian and Baker, 1986) then visualized using a Zeiss Axiovert 200 inverted microscope 
equipped with Qimaging retiga exi digital camera (Zeiss, Burnaby, BC)  to capture the 
images. Images were then recorded and edited using OpenLab software (PerkinElmer, 
Waltham, MA). 
 
2.2 Protein extraction 
 
After treatments, cells were briefly washed in ice cold Dulbecco’s phosphate buffer 
saline (D-PBS; Wisent) and harvested with a rubber policeman into 5mL ice cold D-PBS. 
Cells were  spun at 1500rpm for 10 minutes at 4C, supernatants removed and pellets 
resuspended in 500L of protein extraction buffer [25mm Tris pH 7.5, 25mm Glycine, 
150mm NaCl, 1x Complete Protease Inhibitor Cocktail (Roche, Mississauga ON), 1% 
Triton X-100 (Sigma-Aldrich, Oakville, ON) and 5mM EDTA pH 8.0 (Quality Biological 
Inc, Gaithersburg, MD)]. Isolated cells were incubated on ice for fifteen minutes and then 
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centrifuged at 4C for five minutes at 14, 000rpm. Supernatants collected were then either 
used in immunoprecipitations or electrophoretically separated for immune blotting.    
Protein extraction procedures for phosphorylation experiments were performed 
similar to those outlined in 2.2 with the addition of 1mM sodium orthovanadate (Sigma-





2.3.1 Immunoprecipitation of ErbB receptors 
 
 ErbB receptors were immunoprecipitated from samples with equal protein 
concentrations, determined using the Bradford method (Bradford, 1976), in a total volume 
of 500L of lysis buffer. Extracts were incubated with 2g of rabbit anti-ErBB2, -3 or -4 
polyclonal antibody (ErbB2; SC-284, ErBB3; SC-285, ErbB4; SC-283, Santa Cruz 
Biotechnologies, Santa Cruz, CA) with gentle rocking for 60 minutes at 4C. The antibody-
antigen complex was then incubated with 50L of Protein G Agarose beads (50% 
beads/volume; Upstate/Millipore, Billerica, MA) for 60 minutes at 4C with gentle rocking. 
The agarose beads were collected by centrifugation at 1000rpm for 15 seconds at 4C then 
were washed with 1mL of ice-cold wash buffer (150mm NaCl, 50mm Tris pH 8.0, 1% 
Triton x100, 1mm Na3OV4). Beads were washed five times with centrifugation in between 
and then resuspended in 50L of 3x SDS-loading dye; heating for 5 minutes at 95C. 
Prepared samples were stored at -20C until use.  
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2.3.2 Immunoprecipitation of 7AChR 
 
 Cells were first treated as outlined in Table 1 before extraction. For 
immunoprecipitation of 7AChR receptors, equal amounts of protein (1.0-2.5mg/mL) 
contained in a total volume of 500L of lysis buffer were incubated with 1g of biotin-XX-
-bungarotoxin (Biotium Inc, Burlington, ON) with gentle rocking for 60 minutes at 4C. 
The toxin-antigen complexes were then incubated with 50L of streptavidin beads 
(Upstate) for 60 minutes at 4C with gentle rocking. The streptavidin beads were collected 
by centrifugation at 1000rpm for 15 seconds at 4C then were washed with 1mL of ice-cold 
was buffer for a total of five washes with centrifugation in between.  Beads were finally 
resuspended in 50L of 3x SDS-loading dye and heated for 5 minutes at 95C. Samples 
were stored at -20C until use.  
 
Table 1: Treatments for IP used in ELISA and western blot experiments 
Well Label Treatment, incubation time Figure 
C No treatment 3.5-3.10 
N 1nM NRG, 24 hours 3.5-3.10 
L 1mg/mL LPS, 4 hours 3.5-3.10 
N+L 1nM NRG, 24 hours 
1mg/mL LPS, 4 hours  
3.5-3.10 
BSA 1mg/mL BSA, 24 hours 3.5 
A+N 1nM NRG, 24 hours 
500µmol ACh, 23 1/2 hours 
3.6, 3.9, 3.10 
A+N+L 1nM NRG, 24 hours 
500µmol ACh, 23 1/2 hours 
1mg/mL LPS, 4 hours 
3.6, 3.9, 3.10 
  
Table 1 shows the various treatments used before immunoprecipitation. The IP samples were then 
subjected to western blotting and ELISA. The corresponding figures to the various treatments are also 
outlined under the figure heading. NRG treatments were added first to allow for any possible increase in 
transcription of AChR. ACh was added after NRG treatments to allow for activation of α7AChR. Lastly, was 





2.4 Western blotting 
 
2.4.1 ErbB 2-4 expression  
 
 ErbB2-4 expression in microglia and macrophages was confirmed by immunoblot 
using standard protocols (Jacobson et al., 1998). Protein extracts were electrophoretically 
separated by an SDS-polyacrylamide gel and subsequently electroblotted onto 
nitrocellulose membranes. Following blotting, membranes were blocked overnight in 
10mM Tris pH 7.5, 0.15M NaCl and 0.1% Tween 20 supplemented with 2.5% BSA/ 2.5% 
milk.  Blots were probed with rabbit anti-ErbB polyclonal antisera (1:1000; Santa Cruz) for 
1 hour at room temperature. Specific binding was then visualized using a donkey anti-rabbit 
horse radish peroxidase (HRP) conjugated antibody (1:1000 dilution, 1 hour at room 
temperature; Amersham, Arlington Heights, IL) and captured using chemiluminescence 
detection ECL (Pierce, Rockford, IL) on autoradiography film (GE, Mississauga, ON). 
Anti-mouse beta-tubulin (gift from Dr. Mungo Marsden, University of Waterloo, ON) was 
used (1:5000 dilution, 1 hour at room temperature) to ensure equal loading and presence of 
protein in crude cell extracts. Beta-tubulin immunoblots were ran in parallel with anti-ErbB 
antibodies and were visualized using rabbit anti-mouse HRP conjugated antibody (1:2000 
dilution, 1 hour room temperature; Amersham).  
 
2.4.2 Activation of ErbB receptors in the presence of neuregulin 
ErbB IP samples were electrophoretically separated on 8% SDS-polyacrylamide gel 
and transferred onto nitrocellulose membrane as described above (2.4.1). For 
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phosphotyrosine detection, blots were probed with the 4G10 monoclonal anti-
phosphotyrosine antibody (1:1000 dilution, 1 hour room temperature; Upstate 
Biotechnology, Lake Placid, NY) in buffer containing 10mM Tris pH 7.5, 0.15M NaCl, 
0.1% Tween 20 and0.05% IGPAL supplemented with 5% BSA. Specific binding was then 
visualized using a rabbit anti-mouse horse radish peroxidase (HRP) conjugated antibody 
(1:2000 dilution, 1 hour room temperature; Amersham).  
 
2.4.3 Alpha seven acetylcholine receptor expression 
 
 Alpha 7 AChR expression was confirmed by immunoblot using standard protocols 
outlined previously (2.4.1). Blots were probed using rabbit anti-7AChR polyclonal 
antibody (1:500, 1 hour at RT; sc-1447, Santa Cruz) and visualized using a donkey anti-
rabbit horse radish peroxidase (HRP) conjugated antibody (1:1000 dilution, 1 hour at RT; 
Amersham). 
 
2.5 Enzyme Linked Immunosorbent Assay (ELISA) 
 
 To determine if microglia are activated in response to neuregulin treatment the 
concentration of TNF- in cell culture media was determined by ELISA.  
At varying time points, medium was harvested from treated plates (Table 1). TNF- 
concentration was measured using Mouse TNF- ELISA Ready-SET-Go kit (88-7324; 
eBioscience, San Diego, CA) and performed according to procedure accompanying ELISA 
kit. Briefly, 96 well Corning Constar 9018 plates were coated with 100L/well of capture 
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antibody in coating buffer, sealed with parafilm and incubated overnight at 4C. Plates 
were then aspirated and washed five times with 250L/well of wash buffer (1x PBS and 
0.05% Tween-20). Wells were then blocked with 200L/well of 1X assay diluent. After 
incubation for 1 hour at room temperature wells were again washed five times. Next,  
100L/well of TNF- of known concentration at varying dilutions in 1x assay diluent was 
added to wells to create a standard curve (appendix A). Experimental samples were also 
added at 100L/well. The plate was then covered with parafilm and incubated overnight at 
4C. After aspirating and washing five times 100L/well of detection antibody diluted in 
1X assay diluent was added, covered and incubated at room temperature for 1 hour. Plates 
were then aspirated and washed five times. Avidin-HRP diluted in 1X assay diluent was 
added at 100L/well, covered and incubated at room temperature for 30 minutes. Wells 
were then soaked in wash buffer for 2 minutes and aspirated for a total of seven washes. 
Lastly, 100L/well of substrate solution was added and the plated was incubated at room 
temperature for 15 minutes before the addition of 50L/well of stop solution. Plates were 
then read at 450nm using a microplate reader.  
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                                           Chapter 3 Results 
 
3.1 Isolation and identification of microglia from mixed cell populations harvested 
from brain tissue 
 
 There are inconsistencies in the literature regarding which ErbB receptors are 
expressed by microglia (Table 2). This contradictory information appears to depend on the 
cells cultured; with primary and immortalized cells producing divergent results (Dimayuga 
et al., 2002; Gerecke et al., 2001; Chaudhury et al., 2003; Cannella et al., 1999). Due to 
these discrepancies, and the importance of the ErbB receptors in neuregulin signaling, my 
initial investigation analyzed ErbB receptor expression in both primary cells and 
immortalized cell lines.  
Table 2: Reports of ErbB receptors in microglia 
Author, year ErbB receptor present Cell type 
Xu and Ford, 2005 ErbB4 Primary 
Dimayuga et al., 2003 ErbB2-4 N9 (immortalized cell line) 
Chaudhury et al., 2003 ErbB4  and ErbB2 Primary isolated from neuritic 
plaques in Alzheimer’s disease 
Gerecke et al., 2001 ErbB3 and ErbB4 Primary 
Erlich et al., 2002 No early ErbB4 until after injury Primary, conclude that expression 
is due to phagocytosis 
Canella et al., 1999 ErbB3, ErbB2 inconclusive 
ErbB4 in MS 
Normal primary and MS 
  
Table 2 illustrates the current literature with regards to ErbB expression in microglia. Both 
immortalized cells lines and primary cells are represented. ErbB4 expression is solely seen in damaged and 
diseased tissues. Immortalized cell line, N9, shows expression of ErbB2-4 receptors. Primary cells show the 
largest variation with ErbB expression. 
 
 
 Adult and neonate primary microglial cultures were isolated from the brains of 8 
week and P1 to P3 day old mice respectively. Cells isolated from mouse brains were grown 
for two weeks as mixed glial populations prior to purification. Adult microglial cells, when 
isolated, did not grow very well in culture compared to those isolated from neonates 
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(Figure 3.1) and as such were not used extensively. Nonetheless, adult primary cells, when 
extracted and immunoblotted for ErbB receptor expression were shown to not express any 
of the ErbB family of receptors (data not shown).  
Purity of cell cultures was determined by labeling putative microglia with Dil 
labeled Ac-LDL, a microglia specific fluorescent marker for phagocytosis (Figure 3.1, B 
and C). Images were taken at 10x (Figure 3.1, A and B) and 40x magnification (Figure 3.1, 
C) to analyze cell morphology and purity obtained though percentage of fluorescence 
uptake. Analysis of fluorescent uptake quantified from DIC and fluorescent fields of 100 
cells over 3 experiments indicated that the primary microglia cultures were 98% pure +/-
1%. At this level of purity there is very little potential for artifactual errors to be introduced 
by contaminating cells; in this case 1-2% is astroctyes. In my purified microglia, I saw the 
presence of ramified microglia. Existing in 5% of the total purified microglia population, 
ramified microglia are characterized by processes protruding from their soma. Contrasting 
this are amoeboid cells which appear circular in appearance. In addition to differences in 
morphology, ramified cells phagocytose more fluorescence and appear redder than 










Figure 3.1 Establishing the purity of neonate microglia obtained from mixed glial cell 
populations. Differential interference contrast microscopy at 10x magnification of pure 
neonate microglia was used to show the morphology of microglia (A).  Microglial cells 
appear uniform in size, shape and morphology. Most putative microglia appear to be 
amoeboid (indicated by black arrow) while approximately 5% of cells appear to be 
ramified, identified by processes protruding from the soma (yellow arrow).  A rhodamine 
filter set was used to image Dil phagocytosis by microglia. Images have been edited via 
Adobe Photoshop (Adobe Systems Canada, Toronto, ON) to show red corresponding to 
uptake of fluorescence (B and C).The image shown in A has a corresponding fluorescence 
image (B). Red puncta indicated phagocytosis of Dil-Ac-LDL identifying cells as 
microglia. Absence of cells without red puncta confirms successful isolation of microglia 
cells. DIC and fluorescence images were juxtaposed at 40x magnification (C) to confirm 
purity. Primary microglia (C) exists in two forms: amoeboid (indicated by yellow arrow) 
and ramified (indicated by green arrow). Ramified microglia uptake more fluorescence and 
















3.2 ErbB expression in microglial and macrophage cell lines 
 
  
The ErbB receptors are a family of tyrosine kinase receptors that become 
phosphorylated upon ligand binding (Buonanno and Fischbach, 2001). To determine if 
the ErbBs are expressed and verify NRG’s ability to stimulate the tyrosine 
phosphorylation of these receptors, I cultured the murine cell lines, EOC-20, BV-2 and 
RAW 264.7, as well as microglia isolated from postnatal mice as previously described. 
The crude cell extracts where then analyzed by immunoblot for ErbB2-4 receptor 
expression (Figure 3.2 and Figure 3.3).  
In figure 3.2 there is an absence of banding at the molecular mass expected for the 
ErbB receptors. Whole cell extracts of all three immortalized cell lines appear to not 
express any of the ErbB receptors (Figure 3.2) or do so below the threshold of detection 
of this assay. Mouse anti-beta tubulin antibody was also used to ensure that absence of 
banding was due to an absence or low levels of expression and not due to inadequate 
levels of protein loaded into each well.  
 To determine if ErbB expression is below the threshold of detection in my crude 
samples I immunoprecipitated with the various ErbB antisera to purify the ErbB receptors 
from my extracts. In immunoblots of immunoprecipitated samples, ErbB4 is clearly seen 
in EOC-20, BV-2 and RAW 264.7 cells (Figure 3.4). This is a different result from that 
obtained in figure 3.2 where there was an absence in banding at 185kDa representing 
ErbB4 receptors in EOC-20, BV-2 and RAW cells. The expression of ErbB4 in the 
previously mentioned cell lines in figure 3.4 is due to the increased concentration of 
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receptors via immunoprecipitation to allow for low levels of expression that may not 
appear in crude cell extracts.  
In figure 3.3 there is expression of all three ErbB receptors in primary microglial 
cells. Both positive controls (C2 and HeLa) and primary cells show banding at 185kDa 
indicative of ErbB2-4 expression.  
Having determined that ErbB4 is in fact expressed I endeavored to determine if 
these receptors are activated by NRG. To do this extracts isolated from NRG treated and 
control cultures were immunoprecipitated with anti-ErbB antisera and then 
immunoblotted with the anti-phosphotyrosine antibody 4G10 (Figure 3.4).  NRG addition 
should show an increase in ErbB phosphorylation over cells left untreated, this is indeed 









Figure 3.2 Absence of ErbB2-4 receptor expression in whole cell lysate microglia 
and macrophage cell lines. Immunoblots of whole cell lysate from microglial cell lines 
(EOC-20 and BV-2) and macrophage (RAW 264.7) were probed with antibodies specific 
for each ErbB receptor. Arrows on the right of each panel indicate the position of each 
expected immunoreactive species and its mass (185 kDa). The anti-ErbB2 antibody used 
for the immunoblot (top panel) was a rabbit polyclonal antibody specific for the ErbB2 
carboxy terminus (sc-284; Santa Cruz Biotechnologies, Santa Cruz CA). Subsequently, 
the anti-ErbB3 antibody (sc-285) and anti-ErbB4 antibody (sc-283) were also used 
(middle panel and bottom panel respectively). The upper bands at approximately 185kDa 
represent the respective receptor bands (indicated by arrow). Positive control cell lines 
were C2C12 for ErbB2 and 3 and HeLa S3 (H) for ErbB4. Secondary controls (shown at 
right) were probed with secondary antibody only.  Mouse anti-beta-tubulin antibody was 
used to ensure equal loading of cell extracts indicated by the band at the bottom of each 
ErbB panel at 50kDa. EOC-20, BV-2 and RAW 264.7 cells are devoid of banding at 

















Figure 3.3 ErbB2-4 are expressed in primary microglia harvest from mice. 
Immunoblots of whole cell lysate from microglial cells harvested from brains of P1 to P3 
day old mice (P) were probed with antibodies specific for each ErbB receptor. Each lane 
of extracts were obtained from one 10cm dish of confluent cells. Arrows on the right of 
each panel indicate the position of each expected immunoreactive species and its mass 
(185 kDa). The anti-ErbB2 antibody used for the immunoblot (top panel) was a rabbit 
polyclonal antibody specific for the ErbB2 carboxy terminus (sc-284; Santa Cruz 
Biotechnologies, Santa Cruz CA). Subsequently, the anti-ErbB3 antibody (sc-285) and 
anti-ErbB4 antibody (sc-283) were also used (middle panel and bottom panel 
respectively). The upper bands at approximately 185kDa represent the respective receptor 
bands. Positive control cell lines were C2C12 for ErbB2 and 3 and HeLa S3 (H) for 
ErbB4. Secondary controls (shown at right) were probed only with the secondary 
antibody, anti-rabbit HRP. ErbB2-4 expression is seen in primary microglia as indicated 
























Figure 3.4 Expression and phosphorylation of ErbB4 receptors in microglia and 
macrophage cell lines. NRG treated (N) and untreated (C) samples of microglia (EOC 
and BV-2) and macrophage (RAW) cell lines were immunoprecipitated to increase the 
concentration of ErbB receptors. Blots were first probed with antibodies specific for 
phosphotyrosylation (4G10, bottom panel). The anti-phosphotyrosine antibody used for 
the immunoblot was a mouse monoclonal antibody (4G10; upstate signaling). Blots were 
stripped and then reprobed with anti-ErbB2-4 antibodies (IP, top panel). Positive control 
cell lines were C2C12 (C2) for ErbB2 and 3, and HeLa S3 (H) for ErbB4. Negative 
controls were shown right. Beads alone were also immunoprecipitated (data not shown). 
Immunoprecipitated samples (IP) are shown on top with the phosphorylated immunoblot 
(4G10) on the bottom for each receptor.  EOC-20, BV-2 and RAW 264.7 cell lines do not 
possess banding at 185kDa indicative of ErbB2 and ErbB3 expression and 
phosphorylation (ErbB2 and ErbB3). ErbB4 blots show equal size bands in all 
immunoprecipitated samples (top of ErbB4) indicating that ErbB4 is expressed in EOC, 
BV-2 and RAW cells.  4G10 blot of ErbB4 IP samples show a stronger banding with 
NRG treated samples than untreated indicating that NRG is phosphorylating ErbB4 
receptors. Secondary controls (indicated by 2˚) followed same experimental procedures 











3.3 Neuregulin increases α7AChR expression in microglia 
 
 
 In skeletal muscle neuregulin regulates AChR transcription via the ErbB receptors 
(Buonanno and Fischbach, 2001). To determine if NRG has the ability to increase 
α7AChR transcription in microglia and macrophage cells, as it does in muscle, 
immunoblot analysis was performed on extracts isolated from primary cells and cell 
lines. Cultures were treated with NRG, LPS and NRG and LPS (as outlined in table 1) 
and α7AChR were purified by precipitation with a combination of α-BTX biotin and 
streptavidin agarose beads.  Immunoblot analyses were then performed with α7AChR 
antisera to determine if expression changed with treatment (Figures 3.5 and 3.6). 
  In RAW cells I saw no statistically significant changes in α7AChR expression 
with my treatments.  RAW cells treated with NRG increased α7AChR concentration 
1.11± 0.49 fold over untreated cells. Treatment with LPS increased 1.16±0.73 fold and 
NRG combined with LPS increased 1.25±0.19 fold over untreated cells. Combined, these 
results demonstrate that RAW cells showed no difference in α7AChR expression, even in 
the presence of NRG. 
Contrasting this were the results obtained in BV-2 cells.  BV-2 cells when treated 
with NRG overnight showed an approximate 1.53±0.42 fold increase in α7AChR 
expression (n=3, p<0.05, t-test; Figure 3.5 B).  BV-2 cells appeared to show a decrease in 
α7AChR expression when treated with LPS (Figure 3.5A) but when statistical analysis 
was applied, these results were inconclusive (0.76 ± 0.47 compared to untreated cells). 
The difference in neuregulin and LPS treated BV-2 cells were also not statistically 
39 
 
significant due to a high variability in these experiments. These results taken together 
show that NRG does increase α7AChR expression in BV-2 cells.  
 The expression of α7AChR was also analyzed via immunoblot in primary cells 
harvested from P3 day old mice (Figure 3.6). Similar to the results obtained from BV-2 
cells, NRG addition increased α7AChR expression (Figure 3.6). Untreated primary cells 
had undetectable levels of α7AChR expression.  
As can be seen, the treatments were similar to those in my earlier microglial and 
macrophage cells line experiments but with two additional treatments; acetylcholine was 
added in addition to NRG and added to NRG+ LPS (as outlined in table 1). Acetylcholine 
addition was pertinent to the expression of α7AChR in LPS and NRG treated samples.  
NRG and LPS treated microglia showed expression of α7AChRs when ACh was added to 
the treatment (ACh +N+L, Figure 3.6) oppose to zero expression in its absence (N+L, 
Figure 3.6). Interestingly, ACh addition increased α7AChR expression in primary cells 
treated with NRG and LPS. NRG also appears essential for expression of α7AChR in 
primary microglial cells where α7AChR expression in normally absent or expressed at 





Figure 3.5 NRG increases 7AChR expression in microglia and macrophages. 
Microglia and macrophage cell cultures were treated overnight with NRG (N) or left 
untreated (C). LPS (L) was added twenty four hours later for a period of four hours 
before extraction (table 1).  After treatment, cells were toxin-precipitated with biotin 
conjugated α-BTX and streptavidin agarose beads. Immunoblots were probed with a 
rabbit anti-α7AChR polyclonal antibody (1:500 dilutions, Santa Cruz) and visualized 
using a donkey anti-rabbit HRP conjugated antibody (1:1000 dilution, Amersham). The 
lower bands at approximately 55kDa represent α7AChR. Densitometry analysis of 
immunoblot (A) shows a 1.53 ± 0.42 fold increase in α7AChRs over control in NRG 
treated BV-2 cells (n=3, p <0.05, t-test). BV-2 cells appeared to show a decrease in 
α7AChR expression when treated with LPS (A) but when statistical analysis was applied, 
these results were inconclusive (0.76 ± 0.47 compared to untreated cells). Neuregulin and 
LPS treated BV-2 cells also varied greatly in their results (1.47±0.95 fold increase). 
These results taken together show that NRG does increase α7AChR expression in BV-2 
cells. RAW cells treated with NRG showed a 1.11± 0.49 fold increase over untreated 
cells. Treatment with LPS yielded a 1.16±0.73 fold increase and NRG combined with 
LPS showed a 1.25±0.19 increase over untreated cells. Combined, these results 
demonstrate that RAW cells showed no difference in α7AChR expression, even in the 























Figure 3.6 NRG increases 7AChR expression in primary microglia. Primary cells 
harvested from brains of P3 day old mice were treated for twenty four hours with NRG. 
Thirty minutes after NRG addition (indicated by N), acetylcholine was added in the last 
two wells (indicated by ACh label). The following day LPS was added (indicated by L) 
for four hours before protein extraction. After extraction, cells were toxin-precipitated 
with biotin conjugated α-BTX and streptavidin agarose beads. Immunoblots were probed 
with a rabbit anti-α7AChR polyclonal antibody. The upper bands at approximately 
55kDa (indicated by arrow) represent the α7AChR. Untreated cells (labeled C) showed 
an absence of banding along with N and L treated samples. NRG treated cells showed 
presence of α7AChR. Both ACh treated samples also showed α7AChR expression. 
Secondary control (shown right) contains the same concentration of protein loaded into 




















3.4 The concentration of TNF-α remains unaffected by NRG addition  
 
 
 TNF-α is a pro-inflammatory cytokine released by microglia in response to an 
assault to the CNS (Wang et al., 2003). De Simone and colleagues (2005) have shown 
that increases in α7AChR expression can lead to a decrease in TNF-α.  In section 3.3 I 
showed that NRG had an effect on α7AChR expression in BV-2 and primary cells. Since 
α7AChR expression has been inversely related to the expression of TNF-α (Wang et al., 
2003; De Simone et al., 2005), it is possible that NRG in conjunction with ACh might 
reduce TNF-α expression in my microglia cultures.  
 Media extracted from the cultures treated with NRG (24 hours), LPS (4 hours) 
and NRG + LPS (24 hours and 4 hours respectively) were analyzed for TNF-α 
expression. Cell culture medium was taken at 10 minutes, 30 minutes and 240 minutes 
post treatment. Culture medium was refreshed prior to these experiments to evaluate 
basal level expression and to accurately measure effects of the treatments (time = 0). 
Finally to ensure that NRG treatments alone were not inflammatory, I used BSA as a 
control treatment (treated for 24 hours) to identify unintentional activation of microglia.   
Medium was analyzed for TNF-α using an ELISA (Figures 3.7-3.10). 
Concentrations of TNF-α were calculated using a standard concentration curve. This 
curve was constructed by performing two fold serial dilutions of a known concentration 
of TNF-α (1000pg/mL) and plotted on a log-log scale (Figures A.1 and A.2). Slope of the 
standard curve was then used to calculate TNF-α concentration in Figures 3.7 to 3.10.  
 Acetylcholine is a ligand for α7AChR and its effects on TNF-α were also 
measured with respect to NRG. It is possible that NRG is able to increase α7AChR 
45 
 
expression but is unable to have an effect on the anti-inflammatory response unless ACh 
is present. To account for this, the effects of ACh in addition to the previous treatments 
were investigated using an ELISA (Figures 3.9 and 3.10). It has been previously 
established that NRG increases α7AChR (Figures 3.5 and 3.6), therefore the addition of 
ACh to NRG treated samples might reduce the concentration of TNF-α when treated with 
LPS. This is also assuming that my microglial cultures follow similar patterns to the 
microglial cells used by De Simone and colleagues (De Simone et al., 2005). This is not 
the case as seen below and in figures 3.9 and 3.10.  
 In figure 3.7 I have shown that in RAW cells,  the addition of NRG twenty four 
hours prior to LPS treatment does not have an effect on the concentration of TNF-α (610 
±15.98 pg/mL) compared to LPS alone (640 ±4.04 pg/mL) (n=2). However, in LPS 
treated cells the concentration of TNF-α increased compared to untreated cells 
(29.47±1.58 pg/mL, n=2). Therefore in RAW cells, NRG does not have an affect on 
α7AChR (Figure 3.5) or on TNF-α expression (Figure 3.7).  
 Similar to RAW cells, LPS addition in BV-2 cells resulted in an increase in the 
concentration of TNF-α (361.34±179.17 pg/mL) compared to untreated cells (13.98±1.82 
pg/mL) at 240 minutes (n=2; Figure 3.9). The concentration of TNF-α also increased with 
NRG and LPS treatments over untreated cells however the addition of NRG in LPS 
samples did not affect TNF-α concentration (371.35±213.6 pg/mL, n=2; Figure 3.9)  
Surprisingly, the addition of ACh to cells treated with NRG did not affect the 
concentration levels of TNF-α (308.56±43.79 pg/mL) when stimulated with LPS 
compared to cells that did not receive ACh (371.35±213.6 pg/mL) at 240 minutes (n=2).  
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Therefore in BV-2 cells, NRG regardless of ACh addition does not appear to have an 
effect on TNF-α expression. 
 Similar findings were seen in primary microglia (Figure 3.10) as seen in BV-2 
cells (Figure 3.9). LPS addition resulted in an increase in the concentration of TNF-α 
(586.04±17.72 pg/mL) compared to untreated cells (7.03±1.33 pg/mL) at 240 minutes 
(n=2).The concentration of TNF-α remained unchanged with the combination of NRG 
and LPS versus treatments of LPS alone (553.96±23.08 pg/mL, n=2). The addition of 
ACh to cells treated with NRG did not affect the concentration levels of TNF-α 
(547.66±9.66 pg/mL) when stimulated with LPS compared to cells that did not receive 
ACh (553.96±23.08 pg/mL) at 240 minutes (n=2). 
  In summary, ACh addition does not reduce the amount of TNF-α in NRG treated 
primary or BV-2 cells (Figures 3.9 and 3.10). Despite seeing increases in α7AChR when 
treated with NRG, this increase does not correspond to a decrease in TNF-α.  
Additionally, NRG does not have an effect on TNF-α concentration in RAW cells (Figure 
3.7) as expected since NRG also does not affect α7AChR expression in macrophages 
















Figure 3.7 NRG does not affect TNF- expression in macrophages. RAW 264.7 cells 
were the representative macrophage cell line used to show the various treatment effects 
on TNF-α. A standard curve of TNF-α was constructed to determine the concentration 
levels of TNF-α in RAW cells (Figure A.1). Samples with basal levels of TNF-α were 
taken before the addition of various treatments to determine resting levels of the cytokine 
(indicated by 0). Untreated cells (indicated by C) and BSA (BSA) are used as controls for 
this experiment.  Cells were treated with NRG (N) for 24 hours, LPS (L) for 4 hours and 
BSA for 24 hours.  
There was a minimal level of TNF-α present in cells before treatment. The addition of 
NRG 24 hours prior to LPS treatment did not have an effect on the concentration TNF-α 
(610 ±15.98 pg/mL) compared to LPS alone (640 ±4.04 pg/mL) (n=2). LPS treated cells 
did increase the concentration of TNF-α compared to untreated cells (29.47±1.58 pg/mL, 
























Figure 3.8 NRG has no effect on TNF- expression in microglia. BV-2 cells were the 
representative microglial cell line used to show the various treatment effects on TNF-α. 
All values were calculated using the slope of a standard curve of TNF-α at varying 
dilutions (Figure A.1). Basal levels of TNF-α were taken before the addition of various 
treatments to eliminate out resting levels of the cytokine (indicated by 0). Untreated cells 
(indicated by C) and BSA (BSA) are used as controls for this experiment.  Cells were 
treated with NRG (N) for 24 hours, LPS (L) for 4 hours and BSA for 24 hours.  
There is a notable base level of TNF-α which is present before treatment. The addition of 
LPS caused an increase in the concentration of TNF-α (648.44± 5.96 pg/mL) over 
untreated cells (84.88±4.05 pg/mL) at 240 minutes (n=2). The concentration of TNF-α 
remained unchanged regardless of NRG addition to LPS treated cells (651.39±7.88 























Figure 3.9 TNF- expression in BV-2 cells are unaffected by NRG addition even in 
the presence of acetylcholine. All values were calculated using the slope of a standard 
curve of TNF-α at varying dilutions (Figure A.2). Basal levels of TNF-α were taken 
before the addition of various treatments to eliminate out resting levels of the cytokine 
(indicated by 0). Untreated cells (indicated by C) and BSA (BSA) are used as controls for 
this experiment.  Cells were treated with NRG (N) for 24 hours, LPS (L) for 4 hours and 
ACh for 23 1/2 hours. LPS addition resulted in an increase in the concentration of TNF-α 
(361.34±179.17 pg/mL) compared to untreated cells (13.98±1.82 pg/mL) at 240 minutes 
(n=2).The concentration of TNF-α remained unchanged regardless of NRG addition in 
LPS treated cells (371.35±213.6 pg/mL, n=2). The addition of ACh to cells treated with 
NRG did not affect the concentration levels of TNF-α (308.56±43.79 pg/mL) when 
stimulated with LPS compared to cells that did not receive ACh (371.35±213.6 pg/mL) at 

































Figure 3.10 TNF- expression in primary microglia are unaffected by NRG addition 
even in the presence of acetylcholine. All values were calculated using the slope of a 
standard curve of TNF-α (Figure A.2). Basal levels of TNF-α were taken before the 
addition of various treatments to eliminate out resting levels of the cytokine (indicated by 
0). Untreated cells (indicated by C) and BSA (BSA) are used as controls for this 
experiment.  Cells were treated with NRG (N) for 24 hours, LPS (L) for 4 hours and ACh 
for 23 1/2 hours. LPS addition resulted in an increase in the concentration of TNF-α 
(586.04±17.72 pg/mL) compared to untreated cells (7.03±1.33 pg/mL) at 240 minutes 
(n=2). NRG addition did not affect the concentration of TNF-α in LPS treated cells 
(553.96±23.08 pg/mL, n=2). The addition of ACh to cells treated with NRG did not 
affect the concentration levels of TNF-α (547.66±9.66 pg/mL) when stimulated with LPS 
compared to cells that did not receive ACh (553.96±23.08 pg/mL) at 240 minutes (n=2).  





















Chapter 4 Discussion 
 
 
The original objective of this study was to investigate a possible role for 
neuregulin in regulating the anti-inflammatory response. I originally hypothesized that 
NRG, through its binding to the ErbB receptors, might increase transcription of α7AChR 
in microglia. This would be an interesting result as previous work indicates that increases 
in α7AChR expression can lead to a decrease in TNF-α, a known stimulator of 
inflammation (Wang et al., 2003; De Simone et al., 2005). Based on this I further 
hypothesized that by adding NRG to microglial cells prior to stimulation with a mitogen I 
should see a reduction in the amount of TNF-α secreted by microglia upon activation. In 
my thesis, I have documented differences in ErbB expression in primary and 
immortalized cell lines. Using these cell cultures, I have further shown that NRG induces 
the phosphotyrosylation of the ErbB receptors and that NRG does have an effect on 
α7AChR expression. Yet despite being able to increase α7AChR, TNF-α expression 
remains unchanged in NRG treated cells.  
 
 RAW 264.7 cells where used throughout experiments as another control. Since 
most research done on the anti-inflammatory pathway focuses on the PNS, RAW cells 
were used as a representative macrophage cell line. I used RAW cells to ensure that 
experiments were run correctly and that the effects observed in RAW cells could also be 





4. 1 ErbB2-4 are expressed in primary microglia and ErbB4 is expressed in 
immortalized microglia and macrophages 
 
 Immortalized cell lines and primary cells appear to have distinct ErbB expression 
patterns. Here I have shown that immortalized microglia and macrophage cell lines 
express ErbB4 (Figure 3.4) while primary microglia express ErbB2-4 receptors (Figure 
3.3).  
 
Although no research has directly investigated ErbB expression in BV-2, RAW or 
EOC-20 cell lines, a similar immortalized cell line, N9, has been used to investigate ErbB 
expression. Dimayuga and colleagues (2003) show that N9 murine microglial cells 
express ErbB2-4 and are affected by NRG-1 addition. They were able to show that the 
addition of NRG-1 was able to reduce the amount of nitric oxide released by microglia in 
response to an assault (LPS). Nitric oxide release has been shown to trigger the 
expression of pro-inflammatory cytokines such as TNF-α.  Therefore it is possible that 
NRG may also reduce TNF-α produced by microglia. I have shown that in BV-2 and 
EOC-20 cell lines only ErbB4 receptors are expressed (Figure 3.4). Differences between 
my results and the ones obtained by Dimayuga and colleagues (2003) can possibly be 
attributed to the age at which the cells were harvested, the methods associated with 
harvesting and the subtype of microglia harvested. Since two phenotypes exist for 
microglia, amoeboid and ramified, it is possible that this explains the difference in 
results. Ramified microglia appear around P5 (Ling and Wong, 1993) and continue to 
develop throughout the maturing CNS while amoeboid microglia are derived from blood 
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born monocytes and migrate into the CNS (Rezaie and Male, 2002; Wu et al., 1997). 
Amoeboid microglia differentiate into an intermediate form that eventually turns into 
ramified microglia (Rezaie and Male, 2002). Amoeboid and ramified microglia often 
differ in their expression of receptors and phagocytotic activity (Wu et al., 1997; Ling 
and Wong, 1993). Depending on the age at which N9 cells were originally harvested and 
the specific type of microglia cultured (amoeboid or ramified) could account for these 
differences. A comparison of morphologies between the cell cultures using phase 
microscopy could confirm this hypothesis.   
I have shown that primary microglia express ErbB2-4 receptors (Figure 3.3). This 
result is of particular interest since these cells express an additional two receptors not 
shown in immortalized cells lines and differ from results described from the literature 
(Dimayuga et al., 2002; Gerecke et al., 2001; Chaudhury et al., 2003; Cannella et al., 
1999 )(Figure 3.4 and table 2). Current literature suggests that ErbB2 expression in 
microglia is confined to tissues that are diseased or damaged (Table 2; Chaudhury et al., 
2003; Canella et al., 1999). This is a possible explanation as to why ErbB2 expression is 
seen in my primary microglia cultures and not in my immortalized cells. Since microglia 
do phagocytose surrounding debris during damage combined with the fact that both 
neurons and astrocytes do express ErbB2 receptors there is a possibility that these cells 
are the source of the ErbB2 receptors found in primary microglia (Figure 3.3)(Sharif et 
al., 2009; Chaudhury et al., 2003; Gerecke et al., 2001). Before cells were purified, 
microglial cells were grown up in culture with astrocytes which do express ErbB2-3 
(Sharif et al., 2009). Often during purification, cells are damaged and often harvested 
multiple times before a culture becomes pure. The steps required for purification 
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encourage microglia to phagocytose astrocytes. Microglial cells were grown in isolation 
for 24 hours before experimentation so it is possible that any receptors engulfed would 
show during analysis because microglial cells would not have had enough time to 
degrade the components of the engulfed ErbB receptors.  
Phagocytosis poses similar problems in determining the origins of ErbB3 
receptors. Gerecke and colleagues (2001) along with Canella and colleagues (1999) 
support the findings that microglia express ErbB3 receptors. I have also shown that 
primary microglia do express ErbB3 receptors (Figure 3.3). However, again it is possible 
that this result is due to phagocytosis over actual microglial expression.    
Finally, there are differing reports concerning the origins of receptors in 
microglial cells (Chaudhury et al., 2003; Gerecke et al., 2001; Erlich et al., 2002; Canella 
et al., 1999). ErbB4 expression levels are upregulated at the site of injury and disease and 
confocal microscopy has confirmed that some ErbB4 expression is due to the 
phagocytosis of neuronal cells (Erlich et al., 2002). However, since neuronal cells were 
eliminated from my samples at postnatal day one and were cultured at 12-14 days in vivo, 
the likelihood that engulfed neuronal ErbB4 receptors would survive degradation is 
highly unlikely. Engulfment of astrocytes by microglia is also unlikely since cortical 
astrocytes do not possess ErbB4 receptors therefore expression of the ErbB4 receptors in 
microglia are not due to engulfment of astrocytes. Astrocytes obtained from the 
hypothalamus do contain ErbB4 receptors but are in such a small percentage compared to 
cortical astrocytes that their influence is likely negligible (Sharif et al., 2009). It can then 
be concluded that primary microglia, like their immortalized counterparts, do possess 
ErbB4 receptors.  
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A likely explanation to account for the differences in ErbB receptor expression 
could be due to the specific regions where microglia are harvested from.  This could be 
due to differing ErbB expression in microglia attributed to differences in function or due 
to phagocytosis of other cells found within those specific regions. Gerecke and 
colleagues (2001) identified varying populations of ErbB receptors dependant on location 
of isolation and specific cell type (Gerecke et al., 2001). This could mean that ErbB 
receptor expression in microglia could depend on where the cells are harvest from in the 
brain or what population of cells surrounds the microglia at time of harvest. Alongside 
the results obtained from Sharif and colleagues (2009) where astrocyte ErbB expression 
is dependent on location, differences in microglia expression in the brain could be 
attributed to the region at which the cells were harvested as previously mentioned or due 
to the populations of cells surrounding microglia and those cells specific ErbB 
expression.  
It can be concluded that there is at least ErbB4 expression in microglia with the 
possibility of ErbB2 and ErbB3 expression in primary microglia. Future investigations 
should use confocal microscopy to determine if ErbB2 and ErbB3 expression in 
microglia was due to phagocytosis. Additionally, primary cells could be harvested at a 
later date after purification. Having shown that microglia possess ErbB4 receptors, the 










4.2 Neuregulin phosphorylates ErbB4 in microglia and macrophages 
 
 
 Through the use of anti-phosphotyrosine antibodies, I was able to demonstrate 
that microglial ErbB receptors are phosphorylated in response to NRG (Figure 3.4). 
Tyrosine phosphorylation in microglia is important for cell activation (Karpet et al., 
1994) and can be achieved through the binding of NRG to the ErbB receptors (Buonanno 
and Fischbach, 2001). More specifically, ErbB4 receptors in microglia and macrophage 
cell lines were phosphorylated with NRG addition (Figure 3.4). It is not surprising that I 
saw no difference in ErbB2 and ErbB3 receptor phosphorylation with NRG addition as 
these receptors are not expressed in immortalized cell lines (Figure 3.4).  
 Due to the limited supply of primary cells, phosphotyrosylation could not be 
investigated in primary cells. These experiments could help to rule out the ambiguities 
regarding ErbB2 and ErbB3 expression in primary cells. ErbB2 or ErbB3 
phosphorylation with NRG addition, would allow us to conclude that the ErbB receptors 
shown in figure 3.3 were in fact expressed on the cell surface of microglia and not 
derived from the phagocytosis of astrocytes’ receptors.  
 
4.3 Neuregulin affects the expression of α7AChR in microglia 
 
 I have shown that ErbB4 receptors in my microglial cultures become 
phosphorylated with the addition of neuregulin (Figure 3.4). Further, I was able to show 
that NRG addition leads to an increase in α7AChR over untreated cells in BV-2 and 
primary cells (Figures 3.5 and 3.6). Since ErbB4 is the only ErbB receptor present in BV-
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2 cells, it potentially forms homodimers with these initiating a signaling cascade leading 
to increases in α7AChR expression.  
 Primary cells show a similar result to that of BV-2 cells. Neuregulin treatments 
increase α7AChR expression (Figure 3.6) compared to untreated. However, unlike BV-2 
cells, the untreated primary microglial cells have an undetectable level of α7AChR. This 
is perhaps simply a reflection of the amount of material available for loading onto the gel.  
As mentioned previously, the addition of ACh to NRG and NRG + LPS 
treatments provides a closer environment to that which would be found in vivo. The anti-
inflammatory pathway begins with an assault (LPS) which eventually stimulates the 
release of TNF-α in microglia (de Jonge and Ulloa, 2007; Ulloa, 2005). When it is time to 
decrease or eliminate inflammation, the vagus nerve releases ACh to then bind to 
α7AChR thereby decreasing TNF-α release (De Simone et al., 2005; Wang et al., 2003; 
de Jonge and Ulloa, 2007; Ulloa, 2005). When ACh is added to NRG treated cells there is 
an increase in α7AChR expression when LPS is added versus LPS untreated (Figure 3.6).  
Due to the arduous process of culturing primary cells combined with their 
extremely finite populations, α7AChR experimentation was carried out once. Future 
experiments could replicate this immunoblot and provide a more statistical and definite 
answer as to NRG affects on α7AChR expression in primary cells.  
 
4.4 Neuregulin does not affect TNF-α secretion in microglia or macrophages 
 
 In figures 3.5 and 3.6 I have shown that the addition of NRG results in increased 
α7AChR expression. Taking De Simone and colleagues (2005) results into account one 
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might have expected a reduction in TNF-α concentration when microglia were treated 
with NRG and ACh compared to cultures left untreated (De Simone et al., 2005). Instead, 
what was seen was no difference in TNF-α concentration in any NRG treated sample 
(Figures 3.8 and 3.9) despite the addition of ACh. Therefore, contrary to what was 
originally hypothesized, an increase of α7AChR did not relate to a decrease in TNF- α 
concentration at least under these conditions.  
 Possible explanations as to why TNF-α was unaffected by NRG could be due do 
the saturation of ACh and its receptor. Additionally, the incubation time of LPS before 
media extraction could have also resulted in differences in TNF-α concentration. ACh is 
one of the ligands used to activate α7AChR and is normally released by the vagus nerve 
upon stimulation (De Simone et al., 2005; Wang et al., 2003; de Jonge and Ulloa, 2007). 
It is possible that the amount of ACh added was insufficient to mediate the anti-
inflammatory properties of α7AChR. Repeat experiments could be performed using 
varying concentrations of ACh and measuring its effect on TNF-α. Nicotine could also be 
used in place of ACh since it is also a ligand for α7AChR but binds more strongly to the 
receptor (de Jonge and Ulloa, 2007; Ulloa, 2005).  
Varying the LPS treatment incubation time for the ELISA could account for the 
difference in TNF-α concentration. In my ELISA experiments, cells were treated with 
LPS for four hours prior to media extraction. In both rat and mouse systems, four hours 
seems to be the desired incubation time to allow for peak TNF-α concentrations but 
expression has also been seen twenty four hours after addition (De Simone et al., 2005). 
Analyzing the incubation times of LPS prior to media extraction could result in a more 
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desirable incubation time. It is possible that NRG mediated effects require longer 




 There are many differences that exist between using immortalized and primary 
cell cultures. Here I have established that differences do exist in microglial cell lines with 
respect to ErbB receptor expression (Figure 3.3 and Figure 3.4). Immortalized microglia 
posses ErbB4 receptors while primary microglia posses ErbB2-4 receptors.
 Neuregulin is able to increase α7AChR expression in microglia (Figure 3.5). NRG 
mediates these effects by binding to ErbB4 homodimers which then become 
phosphorylated (Figure 3.4) Despite NRG’s ability to affect α7AChRs it is unable to 
change the concentration of TNF-α (Figure 3.8 and Figure 3.9). In conclusion, even 
though NRG is able to increase α7AChRs it is unable to mediate the anti-inflammatory 
pathway.  
 
4.6 Future directions 
 
 As mentioned previously, primary cell cultures and time were the limiting factors 
in this investigation. With more of both the evidence supporting NRG’s ability to 
increase α7AChR expression, in primary cells would be stronger. Additionally, 
phosphorylation and confocal studies on primary cells would help to explain the origins 
of ErbB2 and ErbB3 receptors in primary cells. If by using microscopy the ErbB 
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receptors were localized to lysosomes then the presence of these additional two receptors 
might be attributed to the phagocytosis of astrocytes. Another possible way to rule out 
astrocytes hindrance is to culture the cells longer once purity is obtained but this is not 
easily achieved. Since microglia need to reach a specific confluence with astrocytes 
before they can be cultured on their own, early separation could result in microglia 
populations that do not grow. Also, due to the finite life span of primary cell cultures, 
once purity is reached there is no predetermined amount of time that microglia will live 
for. Having microglia grow for a few more days alone in culture would be an easy way to 
eliminate out contamination if they survive. Possible transfection of primary microglia 
with a virus could result in extended cell survival as seen in EOC-20, BV-2 and N9 
immortalized cell lines.  
 It would be interesting to investigate NRG effects on IL-12, an anti-inflammatory 
molecule released by microglia. Takahashi and colleagues (2006) have shown that using 
α7AChR antagonists inhibited the production of IL-12 (Takahashi et al., 2006). Since 
NRG was shown to increase α7AChR in microglia (Figure 3.5) it is possible that it could 
also regulate the amount of IL-12 released. Similar experiments used for TNF-α could 
therefore be used for IL-12 (ELISA). 
 Being able to regulate the production of pro-inflammatory cytokines in microglia 
through a mechanism dependant on α7AChRs would be beneficial in a number of 
pharmaceutical applications. In particular, dysregulated microglia are believed to play an 
important role in neurodegenerative diseases such as Alzheimer’s disease (AD) (Streit et 
al., 2004; Raivich and Banati, 2004; Chaudhury et al., 2003).  Alzheimer`s disease is 
associated by uncontrolled inflammation, gliosis, neuritic plaques and neuronal death 
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(Chaudhury et al., 2003). Chaudhury and colleagues (2003) found activated microglia 
with increased ErbB4 expression in the neuritic plaques of AD patients (Chaudhury et al., 
2003). In addition to increased ErbB expression, they also found an upregulation of 
NRG-1 in neuritic plaques (Chaudhury et al., 2003). The activation of microglia leading 
to the overexpression of TNF-α also plays a critical role in the pathology of AD (Streit et 
al., 2004). If NRG were able to selectively regulate the amount of TNF-α released by 
microglia it is possible that NRG addition would alleviate some of the damage caused by 
uncontrolled inflammation. In neuritic plaques there is an increase in NRG expression 
therefore it is possible that NRG plays a role in neuroprotection. Dimayuga and 
colleagues (2003) reported that NRG did increase cell viability so it is also possible that 
NRG addition could aid in neurodegenerative disorders. The mechanisms are still 
unknown, but since I was able to show that NRG is able to increase α7AChR levels it is 
possible that NRG still plays a role in neuroprotection. Further studies could look at the 























Figure A.1 Standard Curve of mouse TNF-α concentration used for Figures 3.7 and 
3.8. Calibration curve was constructed by performing two fold serial dilutions of TNF-α 
with a starting concentration of 1000 pg/mL. Slope was used to determine the 






















Figure A.2 Standard Curve of mouse TNF-α concentration used for Figures 3.9 and 
3.10. Calibration curve was constructed by performing two fold serial dilutions of TNF-α 
with a starting concentration of 1000 pg/mL. Slope was used to determine the 
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